Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2 1

Status

Recruiting 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 1Breast 1

Conditions

Neoplasm Metastasis 2Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Neoplasms 1Lymphoma, Non-Hodgkin 1Leukemia, Myeloid, Acute 1Carcinoma, Transitional Cell 1Breast Neoplasms 1

Interventions

pembrolizumab 59Gemcitabine 37Biopsy 33Specimen Handling 32Paclitaxel 30Magnetic Resonance Spectroscopy 30Nivolumab 29Cisplatin 26Carboplatin 25Irinotecan 24Cyclophosphamide 23Fluorouracil 22Bevacizumab 22Docetaxel 21Oxaliplatin 19Leucovorin 18Ipilimumab 17Cetuximab 17Capecitabine 17130-nm albumin-bound paclitaxel 16Everolimus 15Albumin-Bound Paclitaxel 15Trastuzumab 13olaparib 12Pemetrexed 12Erlotinib Hydrochloride 12spartalizumab 11Sorafenib 11Radiosurgery 11trastuzumab deruxtecan 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Neoplasm Metastasis × ALX148 × Clear all
NCT03013218 2025-08-01

A Study of Evorpacept (ALX148) in Patients With Advanced Solid Tumors and Lymphoma (ASPEN-01)

ALX Oncology Inc.

Phase 1 Completed
174 enrolled
Lymphoid

Lymphoma, Non-Hodgkin, Neoplasm Metastasis, Neoplasms

NCT05868226 2025-04-04

PRE-I-SPY-PI

QuantumLeap Healthcare Collaborative

Phase 1 Recruiting
124 enrolled
Breast

Breast Neoplasms, Neoplasm Metastasis, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡